Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-cell Lymphoma
Sponsor: Janssen-Cilag International NV
Listed as NCT00136565, this PHASE2 trial focuses on Peripheral T-cell Lymphoma and remains completed. Sponsored by Janssen-Cilag International NV, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Jan 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen-Cilag International NV
- Lymphoma Study Association
For direct contact, visit the study record on ClinicalTrials.gov .